Bureau Veritas and Trade Technologies Join Forces to Streamline Global Trade Operations
30.3.2026 08:45:00 EEST | Business Wire | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), through its Swiss branch Government Services Division, is pleased to announce a strategic agreement with Trade Technologies, the leading provider of trade finance automation, connectivity and transaction management services. This collaboration is a significant step toward reducing the complexities of international trade operations, particularly in regions where regulatory and inspection controls remain stringent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329411683/en/
Addressing Critical Trade Finance Challenges
The agreement comes at a pivotal time for global trade. Letters of Credit (LCs) continue to serve as essential instruments in international commerce, particularly across the Middle East and Africa, where counterparty risk, foreign exchange controls, sanctions exposure, and regulatory oversight face ongoing challenges.
In many LC transactions, conformity-assessment documents -such as Certificates of Inspection, Certificates of Conformity, or Inspection Reports- are required as part of the documentation package. These documents must be issued prior to export and be verified to ensure LC compliance, which often creates delays and adds operational complexity. The collaboration between Bureau Veritas and Trade Technologies streamlines this process by linking inspection and conformity assessments directly to the trade-finance workflow, enabling faster validation and delivery of the required certificates.
Market Outlook and Growth Potential
The documentary trade sector is forecasted to grow at a 3.1% CAGR through 2029, while receivables finance is projected to expand at 4.2% CAGR during the same period. Documentary trade is expected to remain a core component of the trade finance market well into the 2050s, underscoring the enduring relevance of this collaboration. Current high levels of counterparty and geopolitical uncertainty underscore the value of documentary trade to manage risk in cross-border transactions.
Tangible Benefits for Trade Stakeholders
The collaboration between Trade Technologies and Bureau Veritas promises to deliver meaningful improvements:
- Enhanced Border Efficiency: More streamlined border processes have already contributed to trade cost reductions of up to 5% over the past decade, with ambitious reforms potentially delivering up to 12 percentage points in additional savings.
- Reduced Uncertainty: By combining Trade Technologies' digital trade expertise with Bureau Veritas' deep international trade experience, this collaboration is expected to help exporters, importers, and traders reduce uncertainty and improve visibility.
- Compliance Assurance: The collaboration ensures that applicable standards and/or contractual obligations are met before goods move across borders, strengthening compliance with inspection and conformity requirements.
A Practical Alignment
This strategic collaboration reflects a practical alignment between Trade Technologies, industry-leading digital trade processes and Bureau Veritas’ global network of testing, conformity and inspection experts, enabling better coordination of financial, documentary, and regulatory workflows across global trade corridors.
“Our Certificates of Conformity and Inspection have long served as essential gatekeepers in global supply chains, confirming that goods meet applicable standards before they cross borders”, said Stéphanie Peyrot, Government Services Director for Central Southeast Europe. “Through this collaboration with Trade Technologies, we're now able to integrate these critical documents directly into the trade finance workflow. This means faster processing, greater transparency, and reduced risk for all parties, from exporters and importers to banks and customs authorities. It's about making compliance work for trade, not against it.”
“Bureau Veritas is an important player for vital documents and data to provide certainty of prompt payment under trade finance instruments”, said Kirk Lundburg, CEO of Trade Technologies. “This collaboration simplifies our communication with Bureau Veritas and reduces the time for delivering key data and documents necessary to get our customers paid for their export transactions. We are delighted to partner with Bureau Veritas to reduce risk and complexity for our shared customers.”
***
About Bureau Veritas:
Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers’ excellence and sustainability, the company innovates to help them navigate change.
Created in 1828, Bureau Veritas’ 82,000 employees deliver services in 140 countries. The company’s technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability.
Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit http://www.bureauveritas.com, and follow us on LinkedIn.
Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.
About Trade Technologies:
Trade Technologies is the leading provider of trade finance automation, connectivity, and transaction management services. Established in 1999, the Company has processed almost USD 195 billion in successful trade transactions for thousands of Exporters. Trade Technologies' innovative solutions, including TradeSharp™ and TradeBridge API, automate and digitize the creation, management, and delivery of documents and data between Corporates, Banks and Buyers. With a global presence in 16 offices across Asia, EMEA and North America, the Company offers a unique blend of technology and expert trade services that optimize transaction processing, enhance cash flow, and provide end-to-end visibility. Clients benefit from faster, more reliable payments and reduced costs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260329411683/en/
Contacts
ANALYST/INVESTOR CONTACTS
Laurent Brunelle
+33 (0)1 55 24 76 09
laurent.brunelle@bureauveritas.com
Colin Verbrugghe
+33 (0)1 55 24 77 80
colin.verbrugghe@bureauveritas.com
Romain Gorge
romain.gorge@bureauveritas.com
Inès Lagoutte
ines.lagoutte@bureauveritas.com
MEDIA CONTACTS
Karine Havas
+33 (0)6 68 63 83 18
karine.havas@bureauveritas.com
Frédéric Vallois
+33 (0)6 21 66 31 04
frederic.vallois@bureauveritas.com
Claudia Strasserra
+39 340 3817265
claudia.strasserra@bureauveritas.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IQM Secures €50M Financing to Accelerate Global Growth30.3.2026 09:00:00 EEST | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), today announced it has secured a €50 millionfinancing package from funds and accounts managed by BlackRock. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260329996942/en/ IQM Radiance quantum computer is located in IQM's showroom in Espoo, Finland. This facility will support acceleration of IQM’s technology roadmap, fuel R&D, support entry into additional markets, and advance IQM’s leadership in quantum computing. This facility was secured prior to IQM’s recent announcement of plans to become the first publicly listed European quantum computing company through a merger with Real Asset Acquisition Corp (“RAAQ”). The facility lowers IQM’s overall cost of capital and improves the flexibility and diversity of its capital base. “The financing package comes at a pivotal time for IQM, as we build momen
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom